506388 TumorGenesis® Normal or Transformed Ovary and Fallopian Tube Media (Ince FOMI) (Liquid)

$579.00

Suggested Usage

NORMAL IMMORTALIZED OVARY CELL LINES Immortalized with hTERT-pgp OCE1 Ovarian Surface OCE2 Ovarian Surface

TRANSFORMED OVARY CELL LINES Transformed with hTERT-gfp + LT/st OCLE1 Ovarian Surface OCLE2 Ovarian Surface

TUMORIGENIC OVARY CELL LINES Transformed with hTERT-gfp + LT/st + H-Ras OCLER1 Ovarian Surface OCLER2 Ovarian Surface

NORMAL IMMORTALIZED FALLOPIAN TUBE CELL LINES Immortalized with hTERT-pgp FNE1 Fallopian Non-ciliated FNE2 Fallopian Non-ciliated

TRANSFORMED FALLOPIAN TUBE CELL LINES Transformed with hTERT-gfp + LT/st FNLE1 Fallopian Non-ciliated FNLE2 Fallopian Non-ciliated

TUMORIGENIC FALLOPIAN TUBE CELL LINES Transformed with hTERT-gfp + LT/st + H-Ras FNLER1 Fallopian Non-ciliated FNLER2 Fallopian Non-ciliated

Tan A. Ince, MD, PhD – Fighting Cancer by Keeping Cancer Cells Alive … https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/

Feb 12, 2017 – Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.

Clear
SKU: 506388 Category:

Customer Supplied
To be supplemented with 0-2% fetal bovine serum to media To be supplemented with Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.

Appearance
Red, clear, complete

Colorless)
FOMI Bullet 1 Included (506388B, Supplied as a liquid. Vortex, spin down and add whole vial to 506388.

Storage (506388B)
Liquid is stable at 4°C.

Pink)
FOMI Bullet 2 Included (506388C, Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506388.

Storage (506388C)
Liquid is stable at -20°C

Storage and Stability w/o supplements)
Store at 4°C. Do not freeze. Light sensitive, store in the dark. Stable for 6 months w/o supplements.

(w/ supplements)
Storage and Stability Complete media with supplements is stable for 6 weeks at 4°C. Do Not Freeze. Light sensitive, store in the dark.

Storage (506388B)
Liquid is stable at 4°C.

Storage (506388C)
Liquid is stable at -20°C.

Country of Origin
United States

FOMI Bullet Included (506388B)
Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506388.

Storage (506388B)
Vial is stable at -20°C. Once thawed and added to 506388, the complete media is stable for 6 weeks at 4°C when stored in the dark.

Important Note
Cholera toxin is NOT included in the liquid media nor the bullet. Shipping regulations have made it increasingly difficult to ship. Please procure from your local supplier. Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.

Licensed by TumorGenesisTM. Manufactured for research use by US Biological.

 

 

1. Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive. 2. AE Witt, CW Lee, TI Lee, DI Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EB Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young and TA Ince, Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer, Oncogene, 2016. DOI: 10.1038/ onc.2016.337. 3. A Thakkar, B Wang, M Picon-Ruiz, P Buchwald and TA Ince, Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer, Breast Cancer Res. Treat., 2016, 157, 77–90. 4. TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, LM Selfors, W Liu, K Chen, M Yong, P Buchwald, B Wang, KS Hale, E Cohick, P Sergent, A Witt, Z Kozhekbaeva, S Gao, AT Agoston, MA Merritt, R Foster, BR Rueda, CP Crum, JS Brugge, GB Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 2015, 6, 7419. 5. S Santagata, A Thakkar, A Ergonul, B Wang, T Woo, R Hu, JC Harrell, G McNamara, M Schwede, AC Culhane, D Kindelberger, S Rodig, A Richardson, SJ Schnitt, RM Tamimi and TA Ince, Taxonomy of breast cancer based on normal cell phenotype predicts outcome, J. Clin. Invest., 2014, 124, 859–870.